

EGFR+ NSCLC: Balancing the decision scales

Friday 12 April 2019, 13:00–14:00

Room C – Palexpo, Geneva, Switzerland



Chair's invitation

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium **'EGFR+ NSCLC: Balancing the decision scales'**.

As the treatment landscape for EGFR+ non-small cell lung cancer (NSCLC) continues to change and advance, so too does the need for physicians to carefully consider and weigh up treatment options to ensure their patients receive the best possible care.

During the symposium, our distinguished faculty will first focus on the evidence and experience to date with the currently available targeted treatments, before considering future directions for investigation, which may help to address the remaining unmet needs in EGFR+ NSCLC.

Finally, the faculty will share their perspectives on how to balance the available treatment options and patient characteristics in order to make informed treatment decisions for our patients with EGFR+ NSCLC.

My colleagues and I look forward to welcoming you to Geneva for what promises to be an interesting and highly educational symposium.

Enriqueta Felip, Chair

Thoracic Cancer Unit, Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain

Programme

Chair: **Enriqueta Felip (Spain)**

13:00–13:05	Welcome and introduction	Enriqueta Felip (Spain)
13:05–13:15	Where did we start?	Enriqueta Felip (Spain)
13:15–13:35	Where are we now and what is on the horizon?	Shobhit Bajjal (UK)
13:35–13:50	How can we make balanced treatment decisions for our EGFR+ patients?	Nicolas Girard (France)
13:50–14:00	Q&A	All faculty, facilitated by Enriqueta Felip (Spain)

Light refreshments will be served prior to the symposium